ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

General surgery · JAMA Surg · 2026-09-01

Post hoc analysis of a phase 3 trial in resectable stage III NSCLC: of 314 operated patients, toripalimab plus chemotherapy vs placebo plus chemotherapy gave similar surgical complications, fewer cancelled operations (17.8% vs 26.7%) and more tumour downstaging (80.7% vs 50.7%).

Secondary analysisn = 404
Fang et al. Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial
Oncology · Lancet Oncol · 2026-07-01

In 110 patients with dMMR/MSI-H locally advanced colorectal cancer, adding celecoxib to neoadjuvant toripalimab raised pathological complete response to 89% vs 69% with toripalimab alone (difference 19 points; p=0·014), with similar grade 3 toxicity (5% vs 7%).

RCTn = 110
Hu et al. Neoadjuvant toripalimab plus celecoxib versus toripalimab monotherapy for mismatch repair-deficient or microsatellite instability-high, locally advanced colorectal cancer (PICC-2): an open-label, multicentre, randomised, phase 2 trial
Oncology · Ann Oncol · 2026-01-20

Final analysis in 514 patients with advanced oesophageal squamous-cell carcinoma: toripalimab plus paclitaxel-cisplatin improved overall survival vs placebo plus chemotherapy (median 17.7 vs 12.9 months; HR 0.72). PD-L1 and TMB did not predict benefit (exploratory).

RCTn = 514
Chen et al. Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.